Abstract
Objective: To study the effect of re-combinant human brain natriuretic peptide (rhBNP) in older emergency patients with acute heart failure. Patients and Methods: A total of 130 patients were randomly divided into two groups as: rhBNP treatment group and sodium nitroprusside (SNP) treatment group, half by half. The rhBNP was taken once every three days for treatment. But dose was doubled at first time used. In the whole progress, it measured the concentration of rhBNP. Echocardiography examination and 6-minute walk testing (6MWT) were used to evaluate the improvement of heart function after rhBNP treatment, compared with SNP. Results: It taken vital symptoms assessment according to the clinical manifestations, once every four hours in the whole 48 hours emergency treatment procedure. Compared before and after treatment, there were significant improvement about LVEF (left ventricular ejection fraction), 6MWT and proBNP level changes in rhBNP group. Furthermore, it revealed that there were also significant differences in LVEF, 6MWT and proBNP level changes between rhBNP and SNP group. Conclusion: Recombinant human brain natriuretic peptide (rhBNP) could be used to treat old patients with acute heart failure in emergency with meaningful clinical value.
Highlights
Brain natriuretic peptide is a 32-amino acid poly peptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells [1,2]
All subjects were divided into Recombinant human brain natriuretic peptide (rhBNP) group and sodium nitroprusside (SNP) group randomly by ratio of 1:1
RhBNP as known as neprilysin is the enzyme that metabolizes natriuretic peptides
Summary
Brain natriuretic peptide is a 32-amino acid poly peptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes) [1,2]. This study was according to the declaration of Helsinki and world health organization guidelines to implement It was under the supervision of the Ethics Committee of the Hebei Province Medical University. As for rhBNP group, treated the patients with lyophilized recombinant human brain natriuretic peptide (rhBNP), which were purchased from China medical system holdings Ltd. Intravenous dose were 1.5 μg/kg, following the flow rate of 0.0075 to 0.020 μg/kg/min. Because of severity of disease, all patients were permitted that received other drug treatment, including aspirin, clopidogrel, stains, diuretics, morphine and other vasoactive medications, according to standard heart failure therapies. These medical treatments didn’t constitute confounding factors for this study. Values less than 0.05 were considered to be statistically significant
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.